Vera Therapeutics, Inc. (VERA) Discusses Ultimate Efficacy Outcomes of ORIGIN Section III Trial of Atacicept in IgA Nephropathy October 22, 2026 4:30 PM EDT
Firm Members
Marshall Fordyce – Founder, President, CEO & Director
Matt Skelton – Chief Business Officer
Convention Name Members
Jonathan Barratt
Anupam Rama – JPMorgan Chase & Co, Analysis Division
Ritu Baral – TD Cowen, Analysis Division
Pete Stavropoulos – Cantor Fitzgerald & Co., Analysis Division
Kyuwon Choi – Goldman Sachs Group, Inc., Analysis Division
Farzin Haque – Jefferies LLC, Analysis Division
Ryan Deschner – Raymond James & Associates, Inc., Analysis Division
Mohit Bansal – Wells Fargo Securities, LLC, Analysis Division
Yu He – H.C. Wainwright & Co, LLC, Analysis Division
Dina Ramadane – BofA Securities, Analysis Division
Rami Katkhuda – LifeSci Capital, LLC, Analysis Division
Presentation
Operator
Good day, everybody. Welcome to the Vera Therapeutics October 22 Investor Webcast. [Operator Instructions] This name is being recorded. In case you have any objections, please disconnect presently. I’d now like to show the decision over to Marshall Fordyce. Please go forward.
Marshall Fordyce
Founder, President, CEO & Director
Thanks, and welcome to Vera’s investor webcast at this time. I am Dr. Marshall Fordyce, Founder and CEO of Vera. And on behalf of your entire Vera group and all of our companions, I am thrilled to share with you the ultimate efficacy outcomes of the ORIGIN Section 3 trial of atacicept for the remedy of adults with IgA nephropathy. I am chatting with you from Denver, Colorado, the place the Annual Assembly of the American Society of Nephrology, or ASN, is internet hosting Kidney Week. ASN is the most important affiliation of nephrologists on the planet.
Our knowledge have been introduced this morning by Dr. Jonathan Barratt, the Mayer Professor of Renal Medication on the College of Leicester and the Head of the Renal Analysis Group.
This morning’s open plenary session with hundreds
